4. Balance Sheet Components

Inventory

Inventory at June 30, 2020 and December 31, 2019 consisted of the following:


	June 30,		December 31,
(in thousands)	2020		2019
	(unaudited)
Raw Material	$	631	$	457
Work in Process		875		1,211
Finished Goods		848		461
Inventory	$	2,354	$	2,129

Property and Equipment

Property and equipment at June 30, 2020 and December 31, 2019 consisted of the following:


	June 30,		December 31,
(in thousands)	2020		2019
	(unaudited)
Land	$	396	$	396
Lab equipment		418		411
Clinical equipment		65		65
Software		63		63
Total property and equipment at cost		942		935
Accumulated depreciation		(245)		(225)
Property and equipment, net	$	697	$	710

Depreciation expense was $10,000 and $20,000 in the three and six months ended June 30, 2020. Depreciation expense was $15,000 and $30,000 for the three and six months ended June 30, 2019, respectively.

Intangible Assets

Intangible assets at June 30, 2020 and December 31, 2019 consisted of the following:


	June 30,		December 31,
(in thousands)	2020		2019
	(unaudited)
Developed technology	$	25,000	$	25,000
Accumulated developed technology amortization		(4,861)		(4,028)
Developed technology, net		20,139		20,972
In-process research and development		4,800		8,800
Impairment		—		(4,000)
In process research and development, net		4,800		4,800
Trademarks		300		300
Accumulated trademark amortization		(58)		(48)
Trademarks, net		242		252
Total intangible assets, net	$	25,181	$	26,024

In June 2019, the Company determined that in-process research and development was impaired and recorded an impairment loss of $4,000,000 in the statements of operations for the three and six months ended June 30, 2019. Amortization expense was $422,000 and $843,000 for the three and six months ended June 30, 2020 and 2019.